Gilead Sciences Inc (GILD)

GILD (NASDAQ:Drugs) EQUITY
$102.99
pos +0.00
+0.00%
Today's Range: 102.66 - 103.83 | GILD Avg Daily Volume: 10,599,200
Last Update: 05/06/15 - 10:30 AM EDT
Volume: 1,393,338
YTD Performance: 12.09%
Open: $103.45
Previous Close: $102.99
52 Week Range: $76.80 - $116.83
Oustanding Shares: 1,489,401,683
Market Cap: 156,700,400,444
6-Month Chart
TheStreet Ratings Grade for GILD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 12 10
Moderate Buy 3 3 2 2
Hold 3 2 3 3
Moderate Sell 1 1 1 1
Strong Sell 0 0 0 0
Mean Rec. 1.68 1.56 1.61 1.69
Latest Dividend: 0.43
Latest Dividend Yield: 0.41%
Dividend Ex-Date: 06/12/15
Price Earnings Ratio: 14.38
Price Earnings Comparisons:
GILD Sector Avg. S&P 500
14.38 12.00 28.64
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
7.35% 32.53% 320.37%
GROWTH 12 Mo 3 Yr CAGR
Revenue 122.20 1.97 0.43
Net Income 294.40 3.32 0.62
EPS 305.00 3.39 0.63
Earnings for GILD:
EBITDA 16.32B
Revenue 24.89B
Average Earnings Estimates
Qtr (06/15) Qtr (09/15) FY (12/15) FY (12/16)
Average Estimate $2.65 $2.54 $10.18 $8.82
Number of Analysts 1 1 1 1
High Estimate $2.65 $2.54 $10.18 $8.82
Low Estimate $2.65 $2.54 $10.18 $8.82
Prior Year $2.32 $1.79 $7.91 $10.18
Growth Rate (Year over Year) 14.22% 41.90% 28.70% -13.36%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Some important, but less followed indicators include margin debt, M&A and buyback activity.  
The reasons to analyze one day's market action.
Drug makers, Apple and other tech stocks among reasonable bargains.
And it's not the favorable macroeconomic climate.
Here are Cramer's exclusive comments for the week ahead.
Enjoy today's respite, who knows how long it will last.
Bullish
May 01, 2015 | 8:06 AM EDT
GILD estimates were boosted through 2016, Leerink Partners said. Harvoni is driving growth. Outperform rating and new $128 price target...
Major indices decline more than 1% on the session.
Merger rumors abound around salesforce.com.
What to expect and focus on when these two report this week.

Columnist Conversations

There is a deafening silence of Apple bulls. The way of life is that when the stock drops, nothing - when it r...
The Greek parliament passed legislation last night that basically overturns some of the reforms the country ha...
I for one do not use the 10 yr bond as the only measure of inflation, but if we do look here then we can see f...
Market set to open up despite weaker than expected ADP Jobs Report. Biotech, which has been weak over the past...

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.